Patent · US Active

Therapeutic human anti-IL-1R1 monoclonal antibody

US9534053B2 · kind B2 · utility

2Cited by

17References

21Claims

0Family size

Assignees

AMGEN INC. · US
E.R. SQUIBB & SONS, L.L.C. · US

Inventors

Brian Varnum · Santa Monica, US
Chris Vezina · Newbury Park, US
Alison Witte · Scotts Valley, US
Xueming Qian · Thousand Oaks, US
Francis H. Martin · Newbury Park, US
Haichun Huang · Fremont, US
Gary Elliott · Thousand Oaks, US

Key dates

Filing date	Mar 5, 2014
Grant date	Jan 3, 2017
Priority date	—
Expiry date	May 31, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.